October 2017 Issue Table Of Contents

From The Editor

• In Need Of A Biopharma Bright Spot?

Feature Articles

• Can David Hung Lead Axovant To Alzheimer’s Success?
• Can We Make Innovative Medicines Affordable?
• PROMETIC: New Tech Harvests Orphan Treatments

Capitol Perspectives

• What Does The Trump Pivot Mean For Healthcare?

Companies To Watch

• Madrigal Pharmaceuticals

CEO Corner

• How Moving Up Through The Ranks Can Shape A Biotech CEO

Inside The Industry

• Importing Canadian Drugs Won’t Solve U.S. Pricing Concerns
• Value-Based Healthcare: Pharma’s Role In The Transition
• Why South Korea Is The Hottest Growth Spot For Clinical Trials
• Diversification Relieves Funding Pressure For Small Pharma
• Fostering Innovation Through A Diverse Workforce In Biotech
• A Name Change — And More — For A Biotech
• After The Failed Trans-Pacific Partnership: What Comes Next?
• Can AI Deliver Faster, Better Drug Development?

Leadership Lessons

• How Innovative Organizations Think: Why Rules Matter

Ask The Board

• What Are Your Thoughts On The New FDA Commissioner’s (Scott Gottlieb) Proposal To Make Generic Drug Approval Easier, And Do You Agree That The Impact Will Be A Lowering Of Drug Pricing?
• What’s Next In Processes And Facilities?
• What Are You Doing To Address Some Of The Common Challenges Confronting The Industry (E.G., Industry Image, Clamor For Government Intervention)?